Valvoline Global Operations has pledged $1 million to The Leukemia & Lymphoma Society over the next five years, according to a press release.
The investment is in dedication to LLS’ Dare to Dream Project: an organization working to establish consistency in cancer drugs and provide safer options for pediatric cancer treatment in children.
The Dare to Dream Project is funding the first pediatric AML Data Commons, a platform working to establish consistency in global data reporting, as well as the first global pediatric acute leukemia Master Clinical Trial, LLS PedA.
“With Valvoline Global's presence in over 140 countries, the Dare to Dream Project is especially important to us as it strives to impact lives worldwide,” said Valvoline Global CEO and President Jamal Muashsher. “We are honored to join LLS in this essential global effort.”
“We are grateful to Valvoline Global for their commitment to transforming treatment and care for kids with blood cancer,” said E. Anders Kolb, MD, president and CEO of LLS. “Through their generous support of Dare to Dream, LLS will be able to reach and support many more of the children and families who need us.”
